Nexalin Technology, Inc. (NXL)
NASDAQ: NXL Ā· Real-Time Price Ā· USD
1.380
-0.010 (-0.72%)
At close: Nov 20, 2026, 4:00 PM EST
1.370
-0.010 (-0.72%)
After-hours: Nov 20, 2026, 7:28 PM EST
Nexalin Technology Revenue
Nexalin Technology had revenue of $78.30K in the quarter ending September 30, 2026, with 331.43% growth. This brings the company's total for the last twelve months to $277.31K, up 76.71% year-over-year. In the year 2025, Nexalin Technology had annual revenue of $301.65K with 78.78% growth. That makes Nexalin Technology the 45,203rd largest company in the world by revenue and 6,533rd in the United States.
Revenue (ttm)
$277.31K
Revenue Growth
+76.71%
P/S Ratio
6.15
Revenue / Employee
$34,663
Employees
8
Market Cap
1.71M
Revenue by Geography
- China 190.30K 63.1%
- United States 111.35K 36.9%
Fiscal year ended Dec 31, 2025 See the full Nexalin Technology breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 301.65K | 132.93K | 78.78% |
| Dec 31, 2024 | 168.72K | 57.97K | 52.35% |
| Dec 31, 2023 | 110.75K | -1.21M | -91.62% |
| Dec 31, 2022 | 1.32M | 1.18M | 817.20% |
| Dec 31, 2021 | 144.07K | -98.85K | -40.69% |
| Dec 31, 2020 | 242.91K | 35.53K | 17.13% |
| Dec 31, 2019 | 207.38K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vivos Therapeutics | 20.53M |
| Nuwellis | 9.01M |
| Beyond Air | 8.19M |
| INVO Fertility | 8.00M |
| VolitionRx | 3.44M |
| 20/20 Biolabs | 2.00M |
| Co-Diagnostics | 858.89K |
| Adagio Medical Holdings | 137.00K |
NXL News
- 10 days ago - Nexalin Technology Quarterly report: Q3 2026 - Filings
- 16 days ago - Nexalin Technology Proxy statement: Proxy filing - Filings
- 26 days ago - Nexalin Technology publishes results from 15 mA DIFS technology in Alzheimerās - TheFly
- 26 days ago - Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS⢠Significantly Improves Sleep Quality in Patients with Mild Alzheimer's Disease - GlobeNewsWire
- 26 days ago - Nexalin Technology Proxy statement: Proxy filing - Filings
- 6 weeks ago - Nexalin Technology regains compliance with Nasdaq requirement - TheFly
- 6 weeks ago - Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing - GlobeNewsWire
- 6 weeks ago - Nexalin Technology Registration statement: Registration filing - Filings